News
NICE publish final guidance recommending Aspaveli in adults with ultra-rare blood disorder
The drug is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
The drug is additionally undergoing assessment with the Medicines and Healthcare products Regulatory Agency for a marketing authorisation in the UK.